Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Conditions

Myasthenia Gravis 3

Interventions

rozanolixizumab 10zilucoplan 7ravulizumab 7efgartigimod alfa 6eculizumab 5fludarabine 4Cyclophosphamide 4telitacicept 3Tacrolimus 3HBM9161 3inebilizumab 2Mycophenolic Acid 2Diagnostic Self Evaluation 2Amifampridine 2satralizumab 1rhoA GTP-Binding Protein 1remibrutinib 1iscalimab 1iptacopan 1Robotic Surgical Procedures 1Prednisone 1Prednisolone 1Plasmapheresis 1Immunoglobulins, Intravenous 1Data Collection 1Cladribine 1CK-2017357 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Myasthenia Gravis × HBM9161 × Clear all
NCT05332210 2026-04-28

Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis

Harbour BioMed (Guangzhou) Co. Ltd.

Phase 3 Completed
111 enrolled

Myasthenia Gravis

NCT04346888 2023-03-08

A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients

Harbour BioMed (Guangzhou) Co. Ltd.

Phase 2 Completed
30 enrolled

Myasthenia Gravis

NCT05039190 2023-03-08

MG

Harbour BioMed (Guangzhou) Co. Ltd.

Phase 3 Completed
132 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡